A growing number of findings indicate that GA treatment also leads to augmentation of neuroprotective processes, such as elevation of neurotrophic factors including brain derived neurotrophic factor (BDNF) in EAE-mice as well as in MS patients [35,36,37]. This evidence concerns the gene BDNF and myeloid sarcoma.